SHANGHAI FUDAN-ZHANGJIANG BIO-PHARMACEUTICAL CO.,LTD.

Highlights Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.

Equities

1349

CNE1000000W4

Market Closed - Hong Kong S.E. Other stock markets 04:08:05 2024-05-31 am EDT			5-day change	1st Jan Change
2.06 ^HKD	+0.49%		-1.90%	-19.22%

Apr. 29	Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 22	Shanghai Fudan-Zhangjiang Buys Structured Deposits Worth 200 Million Yuan	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 29	CI
Fudan-Zhangjiang Bio Sees Profit, Revenue Drop in 2023	Mar. 31	MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Proposes Final Ordinary Dividend for the Year Ended December 31, 2023, Payable on August 26, 2024	Mar. 28	CI
Fudan-Zhangjiang Bio's 2023 Profit Falls	Feb. 26	MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 23	CI
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Receives the Acceptance Notice for the Application	Dec. 18	CI
Chinese Regulator NMPA Grants Acceptance Notice for Shanghai Fudan-Zhangjiang's Investigational Drug	Nov. 13	MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Receives the Acceptance Notice for the Investigational New Drug	Nov. 13	CI
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Receives Notification of Approval for Supplementary Drug Application	Nov. 08	CI
Fudan-Zhangjiang's Profit Drops 70.5% in Q3	23-10-31	MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-30	CI
Fudan-Zhangjiang Bio Gets Nod for Cancer Drug Trial	23-10-23	MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Receives Acceptance Notice Issued by the National Medical Products Administration of the PRC	23-10-20	CI
Fudan-Zhangjiang Bio Swings to Profit in H1	23-08-11	MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Announces First Patient Enrolled in Phase I Clinical Trial of FZ-AD004 Antibody Drug Conjugate for the Treatment of Advanced Solid Tumors	23-08-09	CI
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-02	CI
Fudan-Zhangjiang Bio to Swing to H1 Profit	23-07-18	MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Provides Earnings Guidance for the Six Months Ended 30 June 2023	23-07-18	CI
Fudan-Zhangjiang Bio to Invest 150 Million Yuan in Structured Deposit Product from ICBC	23-06-05	MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Approves Final Dividend for the Year Ended December 31, 2022, Payable on or Before August 25, 2023	23-05-30	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.

Equities

1349

CNE1000000W4

Highlights

Filters